Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

Core Insights - UroGen Pharma Ltd. announced the publication of pivotal Phase 3 ENVISION trial results for ZUSDURI, showing a 72.2% probability of remaining event-free at 24 months after achieving complete response at three months, which had a rate of 79.6% [1][2][3] Company Overview - UroGen Pharma is a biotech company focused on developing innovative solutions for urothelial and specialty cancers, utilizing proprietary RTGel technology for sustained drug release [4][6] - The company’s first product is approved for low-grade upper tract urothelial cancer, and ZUSDURI is its second product approved for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) [6] Product Details - ZUSDURI (mitomycin) is indicated for adults with recurrent LG-IR-NMIBC and is administered through a urinary catheter in an outpatient setting, allowing for non-surgical treatment [4][7] - The treatment involves a six-week induction regimen without the need for maintenance therapy, which is a significant advancement in managing this recurrent disease [2][3] Clinical Data - The ENVISION trial demonstrated a median follow-up time of 23.7 months after complete response, with the median duration of response not yet reached [1] - The most common adverse reactions (≥10%) included dysuria, hematuria, urinary tract infection, and increased creatinine levels, with serious adverse reactions occurring in 12% of patients [3][14] Market Context - Approximately 82,000 people in the U.S. are diagnosed with NMIBC annually, with an estimated 59,000 experiencing recurrence, highlighting the need for effective treatment options [5] - The existing standard of care involves transurethral resection of bladder tumor (TURBT), which can lead to repeated procedures and negatively impact patients' quality of life [2][5]